Ziopharm Oncology is focused on advancing the next generation of immunotherapies to weaponize the existing immune system with Controlled IL-12 or introduce new immune system elements with Sleeping Beauty-modified T cells to this fight against cancer. In addition to developing the next generation of immuno-oncology medicines that target multiple types of cancers, we also are targeting the cost and complexity of delivering gene and cell therapies.
Events & Presentations
Mar 5, 2019 4:30 PM EST
Ziopharm Fourth Quarter 2018 Earnings Call
Jan 23, 2019 12:00 PM EST
AAAS Webinar: Cell and gene therapies for cancer: Future promises and challenges
Ziopharm CEO Laurence Cooper, M.D., Ph.D, is participating in a webinar with the American Association for the Advancement of Science, publisher of Science magazine, on Jan. 23 at noon ET. Register for it online.
Ziopharm Oncology 37th Annual J.P. Morgan Healthcare Conference - Q&A